Background
Primary liver cancer is the third leading cause of cancer-related deaths worldwide. It comprises both hepatocellular carcinoma (HCC) (~ 80% of cases) and intrahepatic cholangiocarcinoma (iCCA; ~ 15%), as well as other rare cancer types [
1]. Both entities are often detected late, have a dismal prognosis, and have limited systemic treatment options [
2,
3]. HCC and iCCA are molecularly very distinct entities: while in iCCA, driver mutations in oncogenes, including Kirsten rat sarcoma virus (
KRAS), are frequently reported [
4], in HCC
RAS and rapidly accelerated fibrosarcoma (
RAF) mutations occur only in a subfraction of less than 5 percent of cases [
5]. Nonetheless, the activation of the RAS/MEK/ERK signalling cascade plays a pivotal role in HCC, given that it is often found to be strongly activated [
6,
7]. In addition, the increased expression of RAS, Mitogen-activated protein kinase kinase (MEK), and ERK confers a dismal prognosis in HCC patients [
8]. Mechanistically, indirect modalities of activation have been defined, which comprise the upregulation of positive modulators of RAS (such as guanine nucleotide exchange factor [
9]) and the downregulation of RAS repressors (GTPase-activating proteins, Sprouty, etc. [
10]). Moreover, paracrine stimulation by the hepatocyte growth factor (HGF), the c-Met ligand, represents another mode of RAS signalling activation [
11]. The contribution of the RAS/MEK/ERK pathway to hepatocarcinogenesis has been studied extensively using the hydrodynamic tail vein injection (HTVI) technique. Surprisingly, the administration of mutated Ras homologues alone was insufficient to elicit tumorigenesis in the liver of immune-competent mice. This event was attributed to the induction of senescence and CD4
+ T-cell-mediated clearing of pre-malignant hepatocytes by
NRASG12V [
12]. However, Ho et al. [
13] demonstrated that adding myristoylated AKT to
NRASG12V resulted in strong cooperativity and the development of HCC with a latency of only 4 weeks. Other studies have since confirmed the requirement of such cooperativity with observed tumorigenesis in
HRAS +
MYC [
14],
RAS +
Bmi1 [
15],
NRAS +
∆N90-β-catenin co-injection models [
5]. In one report, a weak hepatocarcinogenesis with the appearance of HCC by 5 months was also reported following the administration of HRAS
G12V alone, which the author attributed to this particular RAS isoform [
16]. Of note, the authors did not find signs of senescence in this model.
The current work was originally aimed at examining the effect of
Rassf1a knockout on
NRAS-induced carcinogenesis.
RASSF1A is considered a negative feedback regulator of
RAS [
17].
RASSF1A has been implied as a critical tumour suppressor in human hepatocarcinogenesis, where hypermethylation and inactivation of this gene frequently occur [
18]. In accordance with our previous study, which did not show cooperativity with activating
PIK3CA mutations [
19], we could not find an increase in tumorigenesis resulting from
NRASG12V injections. Despite this, we were intrigued by the observation that the injection of
NRASG12V alone was sufficient to induce liver tumours (both in
Rassf1a wildtype and knockout mice) after a latency as short as 3 months. Consequently, the previously described mechanisms of senescence inductions are insufficient to inhibit tumorigenesis in our model, and the unique opportunity of studying the oncogenesis of predominantly RAS/MAPK-driven HCC unfolded.
Of particular interest was the concomitant upregulation of the dual specificity phosphatases 4 and 6 (DUSP4 and 6), whose inactivation has recently emerged as digenic synthetic lethal targets in
NRAS and
BRAF mutant melanoma cell lines acting through ERK hyperactivation [
20]. DUSP proteins can dephosphorylate and inactivate ERK1/2 proteins and are involved in the negative regulation of RAS/MAPK signalling [
21,
22]. Of note, it has previously been hypothesized that DUSPs can restrain excessive RAS signalling, support oncogenic transformation, and counteract the induction of senescence [
21,
23,
24]. Moreover, the strong upregulation of the cancer stem cell marker CD133 was determined as a defining feature already at an early time point of
RAS-dependent hepatocarcinogenesis. This protein has recently been implicated in remedying defects in proliferative signalling [
25]. Cell culture experiments unveiled a clear transcriptional dependence of the latter genes on RAS hyperactivation, and upregulation of DUSP4, DUSP6, and CD133 was confirmed both in HCC and CCA cell lines. Thus, novel features of
RAS dependent-oncogenesis were uncovered, potentially representing therapeutic targets in the important oncological paradigm of
RAS-dependent cancers.
Methods
Constructs and reagents
The original pT/Caggs-V12Nras [
26] had been cloned into the pT3 backbone to generate pT3-CAGGS-NRasV12 [
27]. pT3-CAGGS-NRasV12 was applied with pPGK-SB13 for HTVI as described previously [
27]. The pT3-CAGGS-NRasV12 vector was furthermore used for the transfection of HCC cell lines. pT3-EF1α constituted the empty vector (EV) control. The control group's data have been published previously [
19]. Purification of the plasmids was performed with the Endotoxin-free Maxi Prep Kit (Sigma-Aldrich, St.Louis, MO).
Mouse breeding and genotyping
A
Rassf1a KO founder breeding pair was kindly provided by Dr. Louise van der Weyden (Wellcome Trust Sanger Institute, Research Support Facility, Hinxton, Cambridge, CB10 1SA, UK). Note that the genetic background of
Rassf1a WT and KO mice was C57BL/6 J x 129 Sv. As previously described [
19], the control group of
Rassf1a WT mice was generated by crossing
Rassf1a KO mice with C57BL/6 J mice purchased from Charles River Laboratories (Sandhofer Weg, 97,633 Sulzfeld, Germany). Breeding conditions and PCR verification were identical to our report of
Rassf1a KO with
PIK3CA injections [
19].
Hydrodynamic injections and tissue collection
We followed exactly the previously described protocol [
19]. Mice with an age of 6–8 weeks were subjected to HTVI. The experimental groups comprised: untreated, 1 × phosphate-buffered saline (PBS), empty vector (EV), and pT/Caggs-V12Nras co-injected with pPGK-SB13 in a ratio of 25 to 1 in a total volume of 2 ml 0.9% sodium chloride. The total volume was injected into the lateral tail vein within 5 to 7 s, resulting in temporal right-sided heart failure and increased hydrodynamic pressure in the hepatic veins. The distribution of mice per group is summarized in Supplementary Table
1.
The quality of the injection was defined by the following criteria, which led to the exclusion of the respective mice from further analysis: less than 2 ml of total injection and subsequent unusual behaviour lacking the expected reduction in the movement for at least 60 min. Termination criteria were palpable masses (equivalent to a tumour diameter of about 4 cm), respiratory distress, and lethargy. Animals were euthanized by cervical dislocation, subjected to a standardized autopsy protocol, and livers were photo-documented. Animal breeding and animal experiments were in accordance with protocols by the Mecklenburg-Western Pomeranian federal institution “Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei (LALLF) Mecklenburg-Vorpommern” (protocol number/Aktenzeichen: 7221.3–1.1–052/12).
Cell culture and in vitro experiments
The human HCC cell lines PLC/PRF/5, HLE, HLF, Snu182, Snu387, Snu449, Hep3b, SK-HEP1, MHCC97-L, HuH6, as well as the human hepatoblastoma cell line Hep-G2 and the human cholangiocarcinoma cell lines KKU-M055, KKU-100, KKU213, HuCC-A1, CC-LP-1, OZ, RBE, SG231, TKKK, and YSCCC were cultured in 5% CO2 at 37 °C in a humidified incubator. Cell lines were purchased from ATCC (Manassas, Virginia, USA). Cells were grown in Dulbecco’s modified Eagle medium (Gibco, Grand Island, NY) or RPMI 1640 Medium (Gibco) supplemented with 5% fetal bovine serum (Gibco), 100 mg/mL streptomycin, and 100 U/mL penicillin, 1% 1 M HEPES Buffer (Gibco), 1% 100 mM sodium pyruvate (Gibco) and 1% GlutaMAX™ (Gibco).
The AKT/NRAS cell line was derived from a murine HCC that developed after HTVI of myristoylated AKT
flox/flox and
NRASG12V [
27]. Transfection of Cre recombinase resulted in the AKT Cre/NRAS cell line, which was driven solely by the
NRASG12V oncogene, while AKT was depleted. These cells were maintained in Dulbecco’s modified Eagle medium (Gibco, Grand Island, NY).
For DUSP4 silencing, we seeded cells at a density of 4 × 105 cells in 2 ml of medium per well in 6 well plates. Cells were transfected either with DUSP4 and NEG siPOOL (Catalogue numbers: Dusp4-m-002 and N000-c1-059; siTOOLs Biotech GmbH, Planegg, Germany) using Lipofectamine® RNAiMAX (Thermo Fisher Inc). Lipofectamine and siRNA were diluted and combined in OptiMEM® Reduced Serum Medium (Thermo Fisher Inc.). After an incubation period of 48 h, the transfection was repeated. Subsequently, the cells were harvested after an additional 24 h of incubation with cell scrapers. Cells were pelleted by centrifugation (300 g, 5 min). These pellets were used for further downstream analyses.
For transfections, cells were inspected for viability and confluency of about 70–80% and seeded at a density of 4 × 105 cells in 2 mL of medium per well in a 6-well plate. Cells were transfected with pT3-CAGGS-NRasV12 or empty pT3 vector the following day using Lipofectamine® 2000. Lipofectamine and vectors were diluted in OptiMEM® Reduced Serum Medium and combined. Medium in the wells was discarded, and cells were washed with 1xPBS before the addition of the transfection medium. Cells were harvested and pelleted by centrifugation after 48 h incubation using cell scrapers.
For MEK-inhibition experiments, trametinib (Selleck Chemicals GmbH, Berlin, Germany) and mirdametinib (Selleck Chemicals GmbH) were applied. Cells were seeded in 6 well plates at a density of 3–5 × 105 cells in 2 mL medium per well. The control group was treated with DMSO (concentration matching the highest inhibitor concentration as all inhibitors were dissolved in DMSO). After incubation for 24 h at the indicated concentrations, cells were harvested, and cell pellets were obtained.
TPA (12-O-Tetradecanoylphorbol-13-acetate; P1585, Sigma-Aldrich), a phorbol ester, which induces pERK1/2 via the protein kinase C (PKC) [
28], was administered to the medium in concentrations from 0.5 – 2 µM for (30 and) 60 min. The dimethyl sulfoxide (DMSO) control was matched to the highest concentration of TPA applied. The displayed data is representative of at least 2 technical replicates in a minimum of 2 biological repeats for all performed experiments. The data of these replicates and repeats are shown in Figure S
7 with the designation of the corresponding figures in the main manuscript.
In addition, cell viability assays using the xCELLigence® real-time cell analysis dual plate (RTCA DP) device (OLS OMNI Life Science GmbH & Co KG; Bremen, Germany) were carried out. For impedance-based real-time cell index measurement, cells were grown on E-Plate 16 PET (Agilent Technologies, Inc.). The interval for measurement sweeps was set to 15 min. ~ 5000 cells suspended in a total volume of 150 µl of growth medium were seeded in each well. After 24 h siRNA against DUSP4, 6, the combination of both or SCR was added equivalent to the protocol described above. Afterward, we acquired the measurement for up to 72 h. Raw data were analyzed with the RTCA software (OLS OMNI Life Science GmbH & Co KG). The data were normalized to the timepoint of inhibitor addition.
NanoString® and statistical methods
Total RNA was extracted from 4 samples from each group: empty vector (EV), normal-appearing tissue in NRAS injected mice (NT), and the matched tumorous tissue (T). The concentration was measured on a DeNovix® DS-11 FX + und NanoDrop® ND-1000 (DeNovix Inc., Wilmington, USA), and RINe values were obtained on a 200 TapeStation (Agilent, Santa Clara, USA). The 12 mouse RNA samples that were used for further analyses had RINe values between 7.1 and 9.9 and were adjusted to a concentration of 100 ng/5 µl. Gene expression analysis was conducted using the nCounter® Mouse PanCancer Pathways Panel, which comprises 770 genes from 13 cancer-associated canonical pathways (NanoString, Seattle, USA).
Total RNA from DUSP4 silencing experiments in AKT/NRAS and AKT Cre/NRAS was analyzed in 3 biological replicates each (SCR vs. DUSP4 siRNA) with the nCounter® Mouse PanCancer Pathways Panel. Following the manufacturer’s instructions, 100 ng of total RNA was hybridized overnight with the reporter and capture code set at 65 °C. Excess probes were washed off using a two-step magnetic bead-based purification on the nCounter Prep station (NanoString Technologies). Elution from the beads, immobilization on a cartridge, and subsequent alignment followed. Data were collected using the nCounter Analyzer (NanoString Technologies) at 555 fields of view (FOV) through epifluorescence microscopy and CCD image acquisition.
Data were analysed with the nSolver™ analysis software Version 4.0 (NanoString Technologies). We ascertained that all samples passed quality control in the software. The nCounter Advanced Analysis 2.0 plug-in (NanoString Technologies) was employed for further analysis and hypothesis generation. We selected automated normalization by choosing those genes that minimize the pairwise variation statistics. For visualization, unsupervised clustering was chosen to generate a heatmap based on the normalized data counts of individual mRNAs. Differential expression was displayed as a volcano plot with individual genes’ − log10 (p-value) and log2 fold change compared to the control group. For differential expression analyses, p-value adjustments with the Benjamini-Yekutieli method were selected.
The nSolver path view module was employed to display the undirected global significance score of the included Kyoto Encyclopaedia of Genes and Genomes (KEGG) gene as a heatmap [
29]
Histology and immunohistochemistry, Protein isolation and Western blotting, Nucleic acid extraction and quantitative reverse transcription real-time polymerase chain reaction (qRT-PCR)
Discussion
In this study, we demonstrated that hepatocarcinogenesis can be triggered by the sole HTVI of only
NRASG12V, which opposes previously reported observations where
NRASG12V was insufficient to elicit tumorigenesis [
12]. In the mentioned study, pre-malignant hepatocytes were cleared by the immune system through a process defined by CD4
+ T-cells and macrophages as a purported result of oncogene-induced senescence. One potential explanation for this discrepancy could be the difference in the mouse genetic backgrounds. While C57BL/6 × 129 Sv mice were used in our study, the other investigation had been conducted in a pure C57BL/6 background. Furthermore, in the C57BL/6 × 129 Sv background, we had previously reported a tendency to develop tumours by the HTVI of either
PIK3CA E545K or H1047R alone, which had similarly conflicted with earlier reports, that these alterations would not elicit carcinogenesis in an FVB/N genetic background [
46]. We found no synergism between
Rassf1a knockout and
NRAS, which strengthens our previously reported lack of cooperativity between
Rassf1a and
PIK3CA mutant forms [
19]. Focusing on wildtype animals, the occurrence of tumours following
NRAS injections alone argues for a comparatively high tumour susceptibility in the mixed C57BL/6 × 129 Sv background, although in the literature, the parental strain 129 Sv is described to feature an overall low tumour incidence [
49].
Ultimately, this increased susceptibility provided us with the unique possibility to study the molecular details of a purely
NRAS-defined mode of hepatocarcinogenesis. This is of high interest since it is known that human HCC depends heavily on the activation of the RAS/MEK/ERK signalling cascade [
6]. Even though the frequency of
NRAS and
KRAS mutations combined is relatively low at just under 3%, many more indirect mechanisms exist that lead to a similar net effect on the activity of this pathway, such as the aberrant activation of upstream growth factors and the increase of positive or decrease negative regulators [
50]. Thus, developing models that allow the precise study of RAS/MEK/ERK pathway deregulation in HCC is paramount. Accordingly, in our proposed mouse model, we could determine a strong upregulation of the canonical effectors of RAS signalling, while confirming a robust upregulation of non-canonical or indirect RAS effectors such as p38-MAPK with subsequent NFκB and p–c-Jun. Nonetheless, we could not achieve a complete specificity for the Ras pathway, since the signalling was also dispersed to other oncogenic pathways, particularly to AKT-mTOR signalling, which was mirrored by an increase in RICTOR and targets of mTORC1. Furthermore, we found an upregulation of the Hippo pathway. Thus, a significant crosstalk to other oncogenic pathways occurred, which could pose significant challenges to targeting RAS effectors under active upstream signalling. Indeed, therapeutic concepts have been proposed, for example, for
KRAS mutant pancreatic cancer, in which the combined inhibition of mTORC1/2 and MEK precludes adaptive resistance [
51].
In a more detailed gene expression analysis, we identified several significantly deregulated genes, including
Dusp4,
Dusp6, and
Prom1/CD133. The abundance of upregulated members of the DUSP family led us to further study their association with RAS signalling in HCC. Their concurrent upregulation was particularly interesting, since a recent report had suggested a digenic dependence on DUSP4 and DUSP6 in MAPK-driven cancers [
20].
Initially, we confirmed that high expression of DUSP4 and DUSP6 was indeed a feature of several human HCC cell lines, which argues for the importance of these proteins even in the absence of direct RAS mutations. Experimentally, we could further demonstrate that DUSP4 and DUSP6 upregulation was consistently detected following NRASG12V transfection. More specifically, by using the phorbol ester TPA, we could deduce that ERK activation was required for the observed increase in DUSP4 protein levels, while DUSP6 experienced an inverse regulation by mere ERK activation. Thus, the positive influence on DUSP6 should depend on factors upstream of ERK or other targets unique to RAS activation. One intriguing finding of these experiments was that NRAS transfection led to a paradoxical decrease of pERK levels in the cell line PLC/PRF/5. This observation hints at an overshooting feedback inhibition that can result from robust stimulation of RAS. A similar mechanism for DUSP4 and DUSP6 upregulation could be envisioned in our mouse model of NRAS-induced hepatocarcinogenesis. Indeed, the extreme upregulation of the RAS/ERK pathway could be tempered by DUSP4 and DUSP6 as rheostats, thus potentially favouring evasion of oncogene-induced senescence. Interestingly, when we investigated a purely NRAS-dependent murine cancer cell line, we observed a much higher baseline level of DUSP4 and DUSP6 compared to its dual NRAS and AKT-addicted counterpart, which is suggestive of a certain exclusivity towards the RAS oncogenic pathway.
Whether DUSP4 and DUSP6 serve as oncogenes or tumour suppressors is still under debate [
52]. Silencing of DUSP4 resulted in a pro-proliferative and anti-apoptotic effect in the AKT Cre/NRAS cell line, which was mirrored by an increased growth rate in an impedance-based growth assay. To put this finding into perspective, it has been described that DUSP4 can have opposite effects on proliferation. One paper reported DUSP4 deficiency leading to impaired cell proliferation and cell death in NRAS and BRAF mutant melanoma cells. In contrast, in non-melanoma cell lines with BRAF mutation, DUSP4 silencing did not affect their growth (a glioma cell line and a colorectal cancer cell line) [
53]. Moreover, DUSP4 loss increased invasiveness in pancreatic cancer, and restoration of DUSP4 expression reversed this effect [
54]. Finally, in colorectal cancer models, silencing of DUSP4 enhanced cell proliferation and invasiveness, most reminiscent of the effect we observed in HCC cell lines [
55]. Therefore, higher levels of DUSP4 would rather be suggestive of a function as a tumour suppressor. However, at the same time, it might be envisioned that DUSP4 and DUSP6 maintain pERK at tolerable levels allowing the tumour cells to reach a state of stemness to overcome proliferative insufficiency. Altogether, a definite conclusion for a therapeutic concept targeting DUSP4 cannot be reached here. However, we add another layer of complexity, serving as a note of caution when studying DUSP-targeting therapeutics. The dependency on mutational and cancer entities should be controlled.
Finally, NRAS overactivation was also defined by strong CD133 cancer stem cell antigen upregulation, already present in early tumours. In vitro, we described a hitherto unknown regulation of CD133 protein levels by the RAS pathway activity. This stemness player could also contribute to counteracting oncogene-induced senescence mechanisms.
While NRAS mutations rarely occur in human HCC, they are more frequent in CCA, another primary liver tumour, where we confirmed the dependence of DUSP4 protein expression on the KRAS mutational status in cell lines and patient samples. This finding hints at a conserved mechanism active across different cancer subtypes.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.